Cardiff University | Prifysgol Caerdydd ORCA
Online Research @ Cardiff 
WelshClear Cookie - decide language by browser settings

Differences in the recurrence and mortality outcomes rates of incidental and nonincidental papillary thyroid microcarcinoma: a systematic review and meta-analysis of 21 329 person-years of follow-up

Mehanna, Hisham, Al-maqbili, Taleb, Carter, Ben Richard, Martin, Emma, Campain, Nicholas, Watkinson, John, McCabe, Chris, Boelaert, Kristien and Franklyn, Jayne A. 2014. Differences in the recurrence and mortality outcomes rates of incidental and nonincidental papillary thyroid microcarcinoma: a systematic review and meta-analysis of 21 329 person-years of follow-up. Journal of Clinical Endocrinology & Metabolism 99 (8) , pp. 2834-2843. 10.1210/jc.2013-2118

Full text not available from this repository.

Abstract

Context: There is controversy as to whether papillary thyroid microcarcinoma (PTMC) represents more than one disease entity with different outcomes, requiring different treatment. Objectives: To compare characteristics, outcomes, and factors associated with prognosis of incidental and nonincidental PTMC. Setting and Design: Two reviewers performed searches of online databases (1966–2012), reference lists, and conference abstract books. Longitudinal studies of subjects >16 years old receiving any treatments for papillary thyroid cancer ≤10 mm in size were included. Two reviewers independently screened abstracts and articles, extracted data, and assessed quality of studies using National Institute of Clinical Excellence and PRISMA criteria. Results: Of 1102 abstracts identified, 262 studies were reviewed and 17 studies included, comprising 3523 subjects, with mean follow-up of 70 months and total follow-up of 21 329 person-years. This included 854 subjects with incidental PTMC (follow-up, 4800 person-years; mean tumor size, 4.6 mm [range 3.3–6.7 mm]) and 2669 nonincidental PTMC cases (follow-up, 16 529 person-years; mean tumor size, 6.9 mm [range 5.6–8.0 mm]). The recurrence rate in the incidental group (0.5%; 95% confidence interval [CI], 0–1%, P < .001) was significantly lower than that in the nonincidental group PTMC (7.9%; 95% CI, 5–11%), with an OR of recurrence of 14.7 (95% CI, 5.6–54.8, P < .001) for nonincidental PTMC, compared with incidental PTMC. Lymph nodes were involved in 80% (126/157) of recurrences. On meta-regression, age, sex, size, tumor multifocality, lymph node involvement, and treatment modality were not significantly associated with recurrence. Conclusions: Our meta-analysis strongly suggests the existence of at least two distinct entities of PTMC. Incidental PTMC has different clinical characteristics and a much lower recurrence rate than nonincidental PTMC, suggesting that management protocols should be re-considered. Additional studies with standardized data collection are required to explore potential differences between subgroups of nonincidental PTMC.

Item Type: Article
Date Type: Publication
Status: Published
Schools: Medicine
Subjects: R Medicine > RA Public aspects of medicine
Publisher: The Endocrine Society
ISSN: 0021-972X
Date of Acceptance: 10 April 2014
Last Modified: 31 May 2019 14:30
URI: http://orca-mwe.cf.ac.uk/id/eprint/87645

Citation Data

Cited 59 times in Scopus. View in Scopus. Powered By Scopus® Data

Actions (repository staff only)

Edit Item Edit Item